FORTITUDE-ALS is a clinical trial of an investigational oral drug for the treatment of amyotrophic lateral sclerosis (ALS). This clinical trial is now enrolling participants in both the United States and Canada.
FORTITUDE-ALS is designed to evaluate whether CK-2127107 has an effect on participants with amyotrophic lateral sclerosis (ALS) and what kind of side effects may occur in these participants taking CK-2127107.
CK-2127107 is an investigational medicine that is being evaluated as a potential new medicine which could slow the decline of skeletal muscle function in diseases and conditions associated with muscle weakness or fatigue such as ALS.
To learn more about the trial, please click here.
For a list of trial sites, please click here.
To learn more about how to participate in this clinical trial, please click here.